In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action

2007 ◽  
Vol 60 (6) ◽  
pp. 1391-1394 ◽  
Author(s):  
H. Laue ◽  
L. Weiss ◽  
A. Bernardi ◽  
S. Hawser ◽  
S. Lociuro ◽  
...  
Keyword(s):  
Mechanisms Of Action ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Folate Inhibitors

scholarly journals In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis

2017 ◽  
Vol 72 (5) ◽  
pp. 1355-1358 ◽  
Author(s):  
Dina A. Boikov ◽  
Jeffrey B. Locke ◽  
Kenneth D. James ◽  
Ken Bartizal ◽  
Jack D. Sobel
Keyword(s):  
Vulvovaginal Candidiasis ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Candida Spp

In vitro activity of the novel antibacterial agent ibezapolstat (ACX-362E) against Clostridioides difficile

2020 ◽  
Author(s):  
Beverly Murray ◽  
Cindy Wolfe ◽  
Andrea Marra ◽  
Chris Pillar ◽  
Dean Shinabarger
Keyword(s):  
Therapeutic Potential ◽  
Oral Treatment ◽  
Clinical Development ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Clostridioides Difficile ◽  
Clostridioides Difficile Infection ◽  
Time Kill

Abstract Background Ibezapolstat (ACX-362E) is the first DNA polymerase IIIC inhibitor undergoing clinical development for the oral treatment of Clostridioides difficile infection (CDI). Methods In this study, the in vitro activity of ibezapolstat was evaluated against a panel of 104 isolates of C. difficile, including those with characterized ribotypes (e.g. 027 and 078) and those producing toxin A or B and was shown to have similar activity to those of comparators against these strains. Results The overall MIC50/90 (mg/L) for ibezapolstat against evaluated C. difficile was 2/4, compared with 0.5/4 for metronidazole, 1/4 for vancomycin and 0.5/2 for fidaxomicin. In addition, the bactericidal activity of ibezapolstat was evaluated against actively growing C. difficile by determining the MBC against three C. difficile isolates. Time–kill kinetic assays were additionally performed against the three C. difficile isolates, with metronidazole and vancomycin as comparators. Conclusions The killing of C. difficile by ibezapolstat was observed to occur at concentrations similar to its MIC, as demonstrated by MBC:MIC ratios and reflected in time–kill kinetic assays. This activity highlights the therapeutic potential of ibezapolstat for the treatment of CDI.

scholarly journals Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection

2020 ◽  
Vol 7 (6) ◽  
Author(s):  
Ethan Valinetz ◽  
Helen Stankiewicz Karita ◽  
Paul S Pottinger ◽  
Rupali Jain
Keyword(s):  
Cystic Fibrosis ◽  
Lung Transplantation ◽  
Mycobacterium Avium ◽  
Nontuberculous Mycobacteria ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Avium Infection ◽  
Mycobacterium Avium Infection

Abstract Clofazimine has demonstrated in vitro activity against many nontuberculous mycobacteria. We present the case of a woman with cystic fibrosis who developed disseminated macrolide-resistant Mycobacterium avium infection following lung transplantation treated in part with clofazimine. We describe the novel administration of clofazimine via gastrostomy tube.

scholarly journals In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi

2018 ◽  
Author(s):  
Chayanika Biswas ◽  
Derek Law ◽  
Michael Birch ◽  
Catriona Halliday ◽  
Tania C Sorrell ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Antifungal Compound ◽  
The Novel ◽  
In Vitro Activity

In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia

2002 ◽  
Vol 13 (7) ◽  
pp. 735-742 ◽  
Author(s):  
B-M Frost ◽  
G Lönnerholm ◽  
P Nygren ◽  
R Larsson ◽  
E Lindhagen
Keyword(s):  
Acute Leukemia ◽  
Vitro Activity ◽  
Cytotoxic Agent ◽  
The Novel ◽  
In Vitro Activity ◽  
Chs 828 ◽  
Childhood Acute Leukemia

scholarly journals In Vitro Activities of DX-619 and Comparison Quinolones against Gram-Positive Cocci

2006 ◽  
Vol 50 (6) ◽  
pp. 2255-2257 ◽  
Author(s):  
Paul A. Wickman ◽  
Jennifer A. Black ◽  
Ellen Smith Moland ◽  
Kenneth S. Thomson
Keyword(s):  
Staphylococcus Aureus ◽  
Streptococcus Pneumoniae ◽  
Streptococcus Pyogenes ◽  
Vitro Activity ◽  
The Novel ◽  
In Vitro Activity ◽  
Coagulase Negative Staphylococci ◽  
Gram Positive ◽  
Gram Positive Cocci

ABSTRACT The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.

scholarly journals Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of Resistance

2015 ◽  
Vol 61 (suppl 2) ◽  
pp. S58-S68 ◽  
Author(s):  
James A. Karlowsky ◽  
Kim Nichol ◽  
George G. Zhanel
Keyword(s):  
Mechanisms Of Action ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Mechanisms Of Resistance
Sign in / Sign up

Export Citation Format

Share Document